Patents Examined by Lei Yao
  • Bladder carcinoma biomarkers
    Patent number: 10509034
    Abstract: Disclosed are bladder cancer protein biomarkers, methods of determining whether a patient suffers from or shows recurrence of bladder cancer or early stage bladder cancer, or late stage bladder cancer using the bladder cancer protein biomarkers, a detection system, and kits thereof. Said bladder cancer biomarkers comprise at least one of Coronin-IA, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1, and variants thereof.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 17, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Jean Paul Thiery, Prashant Kumar, Jayantha Gunaratne
  • Podocalyxin and TRA-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent
    Patent number: 10509038
    Abstract: The invention relates to an antibody or an antigen-binding fragment thereof, including a heavy chain and a light chain, with heavy chain complementarity determining regions 1 to 3 having the amino acid sequences of SEQ ID NOS. 1 to 3, respectively, and light chain complementarity determining regions 1 to 3 having the amino acid sequences of SEQ ID NOS. 4 to 6, respectively. In addition, the invention relates to an anti-cancer therapeutic agent including the antibody or the antigen-binding fragment thereof.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: December 17, 2019
    Assignee: CUREMETA THERAPEUTICS, LLC
    Inventors: William Michael Schopperle, Edwin Saavedra Tan, Yawen Ju, Mats Harald Holmqvist, Youngbin Tak, An Mary Holmqvist
  • Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
    Patent number: 10493139
    Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: December 3, 2019
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Zhao Wu, Zhigang Liu, Lei Xiao, Chengfei Pu, Zhiyuan Cao
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10487132
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: November 26, 2019
    Assignee: INMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
    Patent number: 10478497
    Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 19, 2019
    Assignee: HYBRIGENICS S.A.
    Inventors: Susan Benjamin, Cécile Planquette, Rémi Delansorne
  • Anti-galectin-9 antibodies and uses thereof
    Patent number: 10450374
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: October 22, 2019
    Assignees: New York University, PureTech Health, LLC
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • Detection and treatment of CD30 cancers
    Patent number: 10444241
    Abstract: The application provides methods of diagnosis, prognosis, prophylasxis and treatment of CD30+ cancers.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: October 15, 2019
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Tina Albertson, Maria L. Smith
  • Modified latency associated protein construct
    Patent number: 10435451
    Abstract: The present invention provides a fusion protein comprising a latency associated peptide (LAP), a pharmaceutically active agent and an amino acid sequence comprising a dimerization domain, wherein the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising a proteolytic cleavage site. Also provided are nucleic acids enclosing such fusion proteins, process for their preparation, pharmaceutical compositions, kits and uses thereof in medicine.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: October 8, 2019
    Assignee: Stealthyx Therapeutics Limited
    Inventors: Yuti Chernajovsky, Lisa Mullen, Gillian Adams, David James Gould, Hawzheen Muhammad
  • Compositions and methods for treatment of diabetic macular edema
    Patent number: 10428158
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: October 1, 2019
    Assignee: Dyax Corp.
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • Cytotoxic factors for modulating cell death
    Patent number: 10421801
    Abstract: Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 24, 2019
    Inventors: Ananda M Chakrabarty, Tapas K Das Gupta, Vasu Punj, Olga Zaborina, Yoshinori Hiraoka, Tohru Yamada
  • Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
    Patent number: 10414809
    Abstract: The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: September 17, 2019
    Assignee: Academia Sinica
    Inventors: Che-Kun James Shen, Yu-Chiau Shyu
  • Modified J-chain
    Patent number: 10400038
    Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: September 3, 2019
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
  • Method to functionalize cells in human blood, other fluids and tissues using nanoparticles
    Patent number: 10391146
    Abstract: Compositions and methods for inhibiting metastatic cancer cells. The compositions comprise nanoparticles which have incorporated therein leukocyte adhesion molecules and therapeutic molecules exposed on their surface. The nanoparticles may be provided attached to leukocytes. Introduction of these compositions in to the circulation of individuals results in inhibition and reduction of metastatic cancer cells.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 27, 2019
    Assignee: Cornell University
    Inventors: Michael R. King, Michael J. Mitchell, Kuldeepsinh Rana, Elizabeth C. Wayne, Chris B. Schaffer, Siddarth Chandrasekaran
  • Anticancer adjuvant composition containing RIP3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting RIP3 expression, and method for monitoring sensitivity of anticancer drug
    Patent number: 10391115
    Abstract: The present invention relates to a pharmaceutical composition for an anticancer adjuvant containing a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent or activator as an active ingredient. The present invention also provides a method for enhancing cancer cell death, comprising administering a RIP3 protein expression inducing agent or activator in combination with an anticancer drug to cancer cells. Additionally, the present invention relates to a method for screening an anticancer adjuvant which enhances anticancer drug sensitivity by promoting RIP3 expression; and a method for monitoring anticancer drug sensitivity based on RIP3 expression. Therefore, in the case of patients lacking RIP3 expression, the use of a conventional chemotherapeutic agent after inducing RIP3 expression by pretreatment with a demethylating agent may be an effective therapeutic strategy.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: August 27, 2019
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: You Sun Kim, Gi Bang Koo, Jung Ho Yun, Woo Jung Kim, Yu Na Jo
  • Soluble CD80 as a therapeutic to reverse immune suppression in cancer patients
    Patent number: 10377810
    Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 13, 2019
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventor: Suzanne Ostrand-Rosenberg
  • Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
    Patent number: 10365279
    Abstract: Systems and kits are provided which are capable of determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Such systems and kits utilize assays to examine the levels of apoptotic markers, angiogenesis markers, immunomodulation markers, and cell cycle markers and can compare samples from a patient taken at different times to determine the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Methods for determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment with such systems and kits are also provided.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: July 30, 2019
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Indushekhar Persaud
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10364282
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: July 30, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Tumor cell-derived microvesicles
    Patent number: 10352935
    Abstract: The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: July 16, 2019
    Assignees: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Janusz Rak, Khalid Al-Nedawi, Brian Meehan, Abhijit Guha
  • Anti-Galectin-9 antibodies and uses thereof
    Patent number: 10344091
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 9, 2019
    Assignees: New York University, PureTech Health, LLC
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • Immunogenic compositions comprising progastrin and uses thereof
    Patent number: 10335470
    Abstract: The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: July 2, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Pomila Singh, Gurpreet Singh